Solventum Corporation (SOLV)
Solventum is a healthcare company that spun off from 3M, focusing on medical supplies like wound care, dental products, and health information technology.
Is Solventum Corporation a good stock for a UK beginner?
The honest version: Solventum is a healthcare company that spun off from 3M, focusing on medical supplies like wound care, dental products, and health information technology.
Over about 2 years to 2026-07-31. This is the share price only; any dividends would add to it. And it's the USD return - as a UK investor your actual £ return also moves with the exchange rate. Past performance is not a guide to the future, and it could just as easily have fallen.
Based on beta - how much the price swings versus the whole market. Bumpier isn't bad; it just means a rougher ride, which matters more the sooner you might need the money.
Prices move on results, news and the mood of the whole market - no single headline explains a day, and a quiet week is usually just noise, not a signal.
Successful pivot to high-growth digital health solutions.
Failure to compete effectively in the medical tech space.
What does Solventum Corporation do?
Solventum operates as a standalone business after separating from the industrial giant 3M, selling essential medical equipment and software to hospitals and clinics. Revenue comes from selling high-volume medical consumables and digital health tools that doctors rely on daily. How smoothly they handle life as a newly independent company, while trying to return to consistent growth, is what to keep an eye on.
On our factor screen it looks strongest on momentum and value, and weakest on growth.
- !Pays no dividend - the whole return rides on the share price
- !Revenue slipped about 3% over the year
- ✓Very profitable - turns about 17% of sales into profit
- ·Low P/E of 11 vs last year's earnings
- ✓Strong return on shareholder money (ROE 35%)
- Momentum screens high (75/100)
- Strong profit margins on core products
- Essential nature of medical supplies
- Lower volatility compared to the broader market
- Growth screens low (4/100)
- Income screens low (16/100)
- High competition in the medical device sector
- Potential for ongoing restructuring costs
- Regulatory changes affecting healthcare spending
What do Solventum Corporation's numbers mean?
How much money does Solventum Corporation make?
Revenue and profit by quarter, and how much of each sale turns into profit.
Does Solventum Corporation pay a dividend?
No - Solventum Corporation doesn't currently pay a dividend, so the whole return would rest on the share price. Plenty of growing companies reinvest their profits instead of paying them out - neither approach is better or worse, they're just different.
When does Solventum Corporation report earnings, and how did recent quarters go?
Solventum Corporation is next scheduled to report on about 2026-08-05 - dates can move, and we don't predict results; this just tells you when to look.
Each quarter a company reports its results against what analysts expected. ‘Beating’ or ‘missing’ is about that expectation, not whether the business is doing well in absolute terms.
| Reported | Expected EPS: The earnings per share analysts expected for the quarter - the average of their forecasts. 'Beating' or 'missing' is measured against this number. | Actual EPS | vs expected |
|---|---|---|---|
| 2026-05-05 | $1.35 | $1.48 | Beat +9% |
| 2026-02-26 | $1.50 | $1.57 | Beat +5% |
| 2025-11-06 | $1.43 | $1.50 | Beat +5% |
| 2025-08-07 | $1.45 | $1.69 | Beat +16% |
| 2025-05-08 | $1.22 | $1.34 | Beat +10% |
| 2025-02-27 | $1.31 | $1.41 | Beat +8% |
Across the last 6 quarters here, Solventum Corporation came in ahead of what analysts expected 6 times. One quarter is noise, not a trend.
See who else reports over the next two weeks →
Reported vs expected earnings per share (EPS) from published results; the expectation is the analyst consensus, not our view. Report dates are estimates that can move.
More in Healthcare
Eli Lilly
West Pharmaceutical Services, Inc.
Incyte Corporation
The Cigna Group
Zimmer Biomet Holdings, Inc.
Moderna, Inc.
Gilead Sciences, Inc.
Regeneron Pharmaceuticals, Inc.What are the scenarios for Solventum Corporation?
An illustrative range for the year ahead, with the assumption behind each case — not a prediction or a price target.
What are the pros and cons of Solventum Corporation?
How many points the write-up makes each way — a balance check, not a score or verdict.
- Strong profit margins on core products
- Essential nature of medical supplies
- Lower volatility compared to the broader market
- Recent decline in revenue and earnings
- No dividend payments to shareholders
- Uncertainty following the recent spin-off
- High competition in the medical device sector
- Potential for ongoing restructuring costs
- Regulatory changes affecting healthcare spending
The write-up's own warning lights — if these start happening, the case above changes.
- A sustained return to positive revenue growth
- Significant improvement in earnings performance
Built from public filings & market prices, checked for an education-only tone, and never a price target. How we make these →
This plain-English summary was auto-generated on 2026-08-01 from public data and checked for an education-only, no-advice tone (the figures above carry their own, usually fresher, 'as of' date). It's information, never a recommendation.